负面的怀孕结果和心血管疾病:西班牙队列
Marta Miserachs1, Cristina Martinez-Bueno2, Almudena Castro3
1Maternal-Foetal Medicine Unit, Department of Obstetrics, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
Healthcare (Basel, Switzerland)
|April 12, 2025
概括
不良妊娠结果 (APO) 显著增加女性的长期心血管疾病风险. 即使是一个APO也会增加风险,多个APO显示出产后心脏病发作或中风的风险要高得多.
科学领域:
- 心血管健康 心血管健康
- 生殖医学 生殖医学
- 流行病学 流行病学
背景情况:
- 新出现的证据将不良妊娠结果 (APO) 与未来心血管疾病 (CVD) 风险的增加联系起来.
- 怀孕是长期母亲心血管健康的潜在指标.
- 了解这种联系对于早期干预策略至关重要.
研究的目的:
- 评估与没有APO的女性相比,APO的女性心血管事件的长期风险.
- 在西班牙队列中调查特定的APO和随后的心血管疾病之间的关联.
主要方法:
- 在西班牙Vall d'Hebron医院 (2010-2015年) 进行的回顾性纵向队列研究.
- 包括没有先前存在的疾病的妇女;APO包括先兆子,妊娠糖尿病,早产,晚期流产和死产.
- 心血管事件定义为急性心肌梗塞或中风;使用调整模型比较事件风险.
主要成果:
- 在APO和分娩后心血管事件之间发现了显著的关联 (调整HR2.5;95%CI1.4-4.4).
- 经历两个或两个以上的APO与明显更高的风险相关 (调整HR 8.6;95%CI 2.8-26.8).
- 在对传统心血管风险因素进行调整后,关联仍然存在.
结论:
- 不良的怀孕结果,包括先兆子,早产和晚期流产,与长期心血管事件风险增加有关.
- APO可能独立地导致长期心血管健康下降.
- 怀孕突出了对女性心血管健康评估和干预的关键窗口.
相关概念视频
Psychoneuroimmunology: Cardiovascular Disease
19
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
A key area of focus in PNI is the relationship between stress and coronary...
19
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
390
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
390
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
70
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
70
Hormonal Regulation
32.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.7K
Teratogenicity
2.3K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.3K


